MarginsXMarginsX
Home › Markets › Health Care › ANVS

Annovis Bio Inc. (ANVS)

ANVS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7500
-19.02% on the day
Market cap
$46.5M
Nano cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$28.9M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/0001104659-26-027751-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerANVS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001477845
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$28.9M
Operating income-$29.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$19.5M
Total assets$21.1M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
5.2 months
$18.7M cash at June 30, 2026
Share count, 1 year
+134.0%
2025-11-12 to 2026-11-13 · +504.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$4.3M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company expects that its existing balance of cash and cash equivalents, as of September 30, 2026, is not sufficient to fund operations for the period through one year after the date of this filing and therefore, Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$18.7M cash; operating cash flow -$10.8M a quarter.Report 2026-06-30
Shares outstanding62,022,520 (2026-11-13); 26,502,889 a year earlier; 10,262,273 three years earlier.Cover page 2026-11-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-11-05
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-30
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $4.3M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$14.8M-$21.9M$18.7MNo debt tags$010-Q 2026-08-14
Q1 2026
2026-03-31
$0-$17.6M-$9.0M$14.2MNo debt tags$010-Q 2026-05-15
Q4 2025
2025-12-31
$0-$9.8M-$8.9M$19.5MNo debt tags$010-K 2026-03-13
Q3 2025
2025-09-30
$0-$7.3M-$3.5M$15.3MNo debt tags$010-Q 2025-11-12
Q2 2025
2025-06-30
$0-$6.2M-$5.1M$17.1MNo debt tags$010-Q 2025-08-12
Q1 2025
2025-03-31
$0-$5.5M-$8.1M$22.2MNo debt tags$010-Q 2025-05-13
Q4 2024
2024-12-31
$0-$5.9M-$8.3M$10.6MNo debt tags$010-K 2025-03-21
Q3 2024
2024-09-30
$0-$12.6M-$3.2M$12.6MNo debt tags$010-Q 2024-11-08

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-05
Latest annual report10-K2026-03-13
Latest quarterly / interim10-Q2026-11-13
Latest current report
FORM 8-K
8-K2026-11-13
Latest proxyDEFA14A2026-10-07

Source: SEC EDGAR submissions feed, 317 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.7%
1 month-12.3%
3 months-48.0%
Year to date-73.1%
1 year-59.4%
From 52-week high-81.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ATNMActinium Pharmaceuticals Inc. (Delaware)$1.49-9.15%$46.8M
RNXTRenovoRx Inc.$0.9549-8.18%$46.1M
MISTMilestone Pharmaceuticals Inc. Common Shares$0.3650-29.81%$45.4M
NMADNomad Power Solutions Inc.$2.80+19.15%$45.1M
HOWLWerewolf Therapeutics Inc.$0.9908+1.07%$48.2M
TLPHTalphera Inc.$0.8609-4.98%$44.7M
HYFTMindWalk Holdings Corp.$0.9378-8.95%$44.6M
ONCYOncolytics Biotech Inc.$0.3399-8.14%$44.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier